Efficacy of highly active antiretroviral therapy in HIV-1-infected children in Kenya

Pediatrics

Volumn 120, Issue 4, 2007, Pages

  Song, Rinn ^a,c   Jelagat, Justine ^b   Dzombo, Doris ^b   Mwalimu, Marietta ^b   Mandaliya, Kishorchandra ^b   Shikely, Khadija ^b   Essajee, Shaffiq ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b Department of Obstetrics and Gynaecology   (Kenya)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

African children; AIDS; HAART; HIV 1; Kenya

Indexed keywords

GENERIC DRUG; LAMIVUDINE; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BLOOD STORAGE; CD4 LYMPHOCYTE COUNT; CELL STRAIN HEK293; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; EMBRYO; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MALE; PRIORITY JOURNAL; PUBLIC HEALTH; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUGS, GENERIC; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; KENYA; LAMIVUDINE; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 35148813458     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-1122     Document Type: Article

References (30)

1. Joint United Nations Programme on HIV/AIDS, WHO. Report on the Global HIV/AIDS Epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2004. Available at: www.unaids.org/ bangkok2004/GAR2004_html/GAR2004_03_en.htm#P237_35114. Accessed January 29, 2007
2. United Nations Children's Fund. The State of the World's Children 2006. New York, NY: United Nations Children's Fund; 2005. Available at: www.unicef.org/publications/files/SOWC_2005_(English).pdf. Accessed January 29, 2007
3. Joint United Nations Programme on HIV/AIDS/World Health Organization. Treating 3 Million by 2005: Making It Happen - The WHO Strategy. Geneva, Switzerland: World Health Organization; 2005. Available at: www.who.int/3by5/en. Accessed January 29, 2007
4. Nicoll A, Timaeus I, Kigadye RM, Walraven G, Killewo J. The impact of HIV-1 infection on mortality in children under 5 years of age in sub-Saharan Africa: a demographic and epidemiologic analysis. AIDS. 1994;8:995-1005
5. Spira R, Lepage P, Msellati P, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Pediatrics. 1999:104(5). Available at: www.pediatrics.org/cgi/content/full/104/5/e56
6. Taha T, Graham S, Kumwenda N, et al. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics. 2000;106(6). Available at: www. pediatrics.org/cgi/content/ full/106/6/e77
7. USAID/Kenya: Annual Report 2005. Washington, DC: US Agency for International Development. 2005. Available at: http://pdf.dec.org/pdf_docs/ Pdacd866.pdf. Accessed January 29, 2007
8. Central Bureau of Statistics (CBS), Kenya, Ministry of Health (MOH), Kenya, and ORC Macro. Kenya Demographic and Health Survey, 2003: Key Findings. Calverton, MD: Macro International, Inc; 2004
9. Gortmaker S, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528
10. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:725-731
11. Teglas JP, Mayaux MJ, Blanche S. Antiretroviral therapy and mortality among children with perinatal HIV infection. JAMA. 2000;284:2871-2872
12. De Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA. 2000;284:190-197
13. Van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002;2:93-102
14. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004;18:1905-1913
15. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection [pub lished correction appears in MMWR Morb Mortal Wkly Rep. 1998;47:315]. MMWR Recomm Rep. 1998;47(RR-4):1-43
16. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994;43(RR-12):1-10. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/000328990.htm. Accessed January 29, 2007
17. Essajee S, Kim M, Gonzalez C, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS. 1999;13:2523-2532
18. + T-cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116
19. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107
20. Nyandiko WM, Ayaya S, Nabakwe E, et al. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. J Acquir Immune Defic Syndr. 2006;43:418-425
21. Eley B, Davies MA, Apolles P, et al. Antiretroviral treatment for children. S Afr Med J. 2006;96:988-993
22. Ananworanich J, Kosalaraksa P, Pancharoen C, et al. A randomized study of immediate vs deferred HAART in children [abstract]. Presented at: 13th Conference on Retroviruses and Opportunistic Infections (CROI) 2006; February 5-8, 2006; Denver, CO. Abstract 701
23. Van Kooten Niekerk NK, Knies MM, Howard J, et al. The first 5 years of the family clinic for HIV at Tygerberg Hospital: family demographics, survival of children and early impact of antiretroviral therapy. J Trop Pediatr. 2006;52:3-11
24. Eley B, Nuttall J, Davies MA, et al. Initial experience of a public sector antiretroviral treatment programme for HIV-infected children and their infected parents. S Afr Med J. 2004;94:643-646
25. Funk MB, Linde R, Wintergerst U, et al. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS. 1999;13:1653-1658
26. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004;350:2471-2480
27. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med. 1999;341:1874-1881
28. O'Brien DP, Sauvageot D, Zachariah R, Humblet P, Medecins Sans Frontieres. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006;20:1955-1960
29. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20:2315-2319
30. WHO. Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2004